Akadeum Life Sciences Release their Revolutionary Human T cell Activation and Expansion Kit

Akadeum Life Sciences, the global leaders in buoyancy-based cell separation technology, have today announced the release of their ‘Human T Cell Activation & Expansion Kit’ with Buoyancy Activated Cell Sorting (BACS) microbubbles. The first-of-its-kind kit is designed to isolate, activate, and expand T cells from a sample in one simple workflow.

In 2023, CAR T cell therapy can cost between $500,000 and $1,000,000. Being one of the most expensive Medicare diagnosis-related drugs, the collection and manufacturing of T cells plays a large role in this excessive cost. Akadeum Life Sciences microbubble technology provides a more economical, cost-effective solution that is faster, and more adept at maintaining cell physiology. This powerful kit uses BACS microbubble technology to isolate highly pure populations of T cells, activate, and expand them for use in cell therapy.

Current cell isolation methods include magnetic activated cell separation (MACS®) and fluorescence-activated cell sorting (FACS). These techniques are well established yet have limitations, time-consuming workflows, are expensive, and can provide unhealthy cells which can hinder scientific developments. By sidestepping the negative effects of legacy methods, Akadeum’s activation and expansion microbubbles provide scientists and researchers with a quick, more efficacious, and cost-effective solution, ultimately allowing them to provide better treatments for patients.

T cells are labelled with an antibody cocktail targeting CD3 and CD28 co-stimulation to which the activation and expansion microbubbles bind. Due to the natural buoyancy of the microbubbles, the positively selected T cells then gently float to the top of the suspension. Activation and expansion take place at the top surface of the vessel, as T cells expand, they gently fall to the bottom preventing overstimulation and producing a higher cell yield of healthier cells.

This kit is compatible with a wide variety of cell culture systems, including standard well plates, specialty plates (such as Wilson Wolf G-Rex®), or gas-permeable bags, making it easily adaptable to a variety of workflows.

Brandon McNaughton, PhD., Chief Executive Officer and Co-Founder of Akadeum, comments: “Manufacturing and workflow practices need to catch up with the pioneering scientific advancements taking place in the oncology field. This gentle and ecofriendly process has the potential to save cell and gene therapy company’s valuable effort and time, transforming current solutions into more effective and economical treatments. Akadeum’s ‘Human T Cell Activation & Expansion Kit’ is an addition to our expanding portfolio of products. This launch also reinforces Akadeum’s goal of revolutionizing the cell separation industry, propelling us one step closer to getting our product to clinical trials.”

Casey Wegner, Vice President of R&D at Akadeum, added: “The isolation, activation, and expansion of highly purified cells has become a necessity for CAR T cell therapy. The gentle microbubble floatation process not only produces healthier cells, but is also a quicker, more efficient, and cost effective solution compared to outdated legacy methods. Our kit rapidly simplifies, optimizes, and streamlines the cell therapy workflow for professionals, ultimately making cell and gene therapy available for all of those in need.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”